You are here

Final Approval Granted for Generic Xanax

WOODCLIFF LAKE, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer Inc.'s Xanax XR (Alprazolam Extended-Release) Tablets, 0.5 mg, 1 mg, 2 mg and 3 mg. The company intends to launch its product immediately.

Xanax XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.

Barr's Alprazolam Extended-Release tablets will compete in a market that had total annual sales of approximately $83 million for the twelve months ending May 2006, according to IMS sales data.

Source: Barr Pharmaceuticals, Inc.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs